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Introduction
In Japan, implantable cardioverter-deﬁbrillators
(ICD) were approved by the Japanese Ministry
of Health, Labor and Welfare (MHLW) in 1996.1)
The ﬁrst guidelines for ICD were published by the
Japanese Circulation Society (JCS) in 2001,2) then
a revised version was posed on JCS’s website in
2006.3) Cardiac-resynchronization therapy without
(CRT-P) with (CRT-D) implantable deﬁbrillators
were then approved in 2004 and 2006, respectively.1)
The implantation of ICD, CRT-D and CRT-P are
useful for improving the prognosis and/or sudden
cardiac death event rate in patients with heart failure
and/or fatal ventricular arrhythmias (ventricular
tachycardia: VT/ventricular ﬁbrillation: VF).4–11)
This review paper was written mainly to identify
the indications for ICD/CRT-P or CRT-D on the
basis of the 2006 JCS guidelines.3) Further, the
usefulness of pharmacological tests for the choice
of eﬀective drugs to treat lethal arrhythmia and
electrophysiological tests for prognosis, especially
in patients with dilated cardiomyopathy, have been
questioned recently.12) Thus, little attention was
given to those factors in this paper. However, the
presence structural heart disease and LVEF measure-
ments were described in greater detail.
I. The implantation of secondary prevention for
sudden cardiac death
The usefulness of the implantation of ICD in
secondary prevention for the improvement of mor-
tality and sudden cardiac death have been shown by
the guidelines in western countries10) and several
mega-trials.13) Since the recurrence rate of VT/VF
was a very high 10 to 20% during two years in those
patients, the implantation of ICDs were classiﬁed
as a class I indication. Thus, we have to focus on
the following class III indications (and contraindi-
cations) even in patients with ventricular arrhythmia.
1) Ventricular tachyarrhythmias due to a transient
or reversible disorder (eg. acute ischemic disease,
electrolyte imbalance, drugs) when correction of the
disorder is considered feasible and likely to sub-
stantially reduced the risk of recurrent arrhythmias.
2) Incessant VT or VF not controllable by the
appropriate drugs and/or catheter ablation. 3) VT or
VF resulting from arrhythmia amenable to surgical
or catheter ablation; for example, atrial arrhythmia
associated with the Wolﬀ-Parkinson Syndrome, and
idiopathic VT. 4) Terminal illness with projected
life expectancy less than six months. 5) Patients with
signiﬁcant psychiatric illnesses that may not coop-
erate with or accept device implantation. 6) NYHA
Class IV drug-refractory congestive heart failure in
patients who are not candidates for cardiac trans-
plantation.
II. Implantation for primary prevention for
sudden cardiac death
Implantable deﬁbrillation devices (ICD/CRT-Ds)
have several problems shared with standard pace-
makers, such as trouble with leads, infection and
infrequent operation-related complications.6,10) Fur-
ther, the speciﬁc troubles associated with shock
therapy, such as the aggravation of cardiac func-
tion14) (the factor of readmission, harm to the cardiac
muscle and deterioration of cardiac function caused
by the back-up pacing), the high cost, inappropriate
shocks, in tolerance of shock therapy,15) and, ﬁnally,
the diﬃculties associated with driving and the ability
to work. Therefore, the primary prevention indica-
tions of these devices should be carefully consid-
ered. On the other hand, it have been reported
that the implantation therapeutic divices was more
eﬀective in the improvement of mortality and
sudden cardiac death than conventional drugs ther-
apy.16,17) The ﬁrst indication we should consider
is whether or not patients have structural heart
disease.
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1. Indications of primary prevention implantation
in patients without structural heart disease
(Figure 1)
Patients without structural heart disease are
counterindicated for shock device implantation,
even if they have syncope and/or ventricular
arrhythmia, excluding those with speciﬁc disease
such as Brugada syndrome and congenital long
QT syndrome. In this review, the indications in
patients with Brugada syndrome and congenital
long QT syndrome are according to the 2007 JCS
guideline.18)
Brugada syndrome was diagnosed as the sponta-
neous or drug-induced appearance of coved type ST
elevation at the right precordial leads. The annual
event rate in patients with asymptomatic Brugada
syndrome was 0.5% in Japan,19) the indication of
device implantation must be carefully consideration
because of the risk (although relative low), the poor
cost-eﬀectiveness and the reduction of QOL. A
history of syncope due to undetermined cause, a
family history of sudden cardiac death and inducible
ventricular ﬁbrillation are considered to be risk
factors for sudden cardiac death in asymptomatic
Brugada syndrome. The indication of device im-
plantation is class IIa when patients have 2 risk
factors, and class IIb when patients have only one
risk factor.18) (Figure 1)
The indication of primary prevention in patients
with long QT syndrome is determined by the number
of risk factors in patients with a history of syncope
due to unknown cause, a family history of sudden
cardiac death, and ineﬀective use of -blockers.
Similaly to the indication in patients with Brugada
syndrome, the indication of device implantation
is class IIa when patients have 2 risk factors, and
class IIb in patients with only one risk factor.
(Figure 1). There is no mention regarding counter
indications (class III) of device implantation in
patients with long QT syndrome.18)
There was no mention about the indications for
family members of patients with idiopathic VF. We
should consider the indication of ICD when VT/VF
was inducible. Whether to counter indicate device
implantation cold not be determined when VT/VF
was not inducible in the partient.
2. Indications of primary prevention implantation in
patients with structural heart disease
More than 80% of structural heart disease in
patients with devices in Japan had old myocardial
infarction or dilated cardiomyopathy For this reason
Figure 1 Indication in primary prevention for sudden cardiac death.
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LVEF is considered as the most important predictive
value of prognosis in those patients (Figure 1).
LV dysfunction (LVEF 35%): The indication of
device implantation in patients with severe LV
dysfunction (LVEF 35%) is classiﬁed as class IIa
even if no ventricular arrhythmia is present. Though
non-sustained VT and inducible VT/VF were high
risk factors in patients with severely compromised
LV function, ICD reduced the number of sudden
cardiac death in patients with or without non-
sustained VT and/or inducible VT/VF.
In the patients with LVEF 35%, drug resistant
CHF (New York Heart Association; NYHA class
III/IV), intraventricular conduction disturbance (a
QRS width 130ms) and with or without a history
of fatal ventricular arrhythmias, the implantation of
CRT-P or CRT-D were classiﬁed as class I indica-
tion.3) The degree of improvement of LV dyssyn-
chrony by CRT-P or CRT-D had a good correlation
to the prognosis. QRS width is the simplest method
to assess LV dyssynchrony.20) The clinical applica-
tions of the pacing method known as CRT alone
(CRT-P) began by using an epicardial lead in
1994.21) Recent meta-analysis11,22,23) demonstrated
that CRT-P improved LVEF, QOL, and functional
status, and reduced hospitalization for heart failure
and mortality from all causes. However, it has not
been determined whether CRT-P has a potential to
suppress lethal arrhythmia or sudden cardiac death22)
(Figure 2).
LV dysfunction (LVEF 36%–50%): There was no
mention about the indication of device implantation
in patients with moderate LV dysfunction (LVEF
36%–50%) in 2006 JCS guideline.3) Therefore, the
patients with non-sustained VT and/or syncope of
unknown etiology may be indicated for device
implantation, when hemodynamically signiﬁcant
sustained VT/VF is induced. Further, for syncope
of unknown etiology, device implantation is indi-
cated in patients with cardiomyopathy even if VT/
VF cannot be induced.
LV dysfunction (LVEF >50%): ICD implantation
may be indicated for hypertrophic cardiomyopathy
as a structural heart disease in this category. Device
implantation is indicated when patients have a
history of syncope, non-sustained VT or sudden
cardiac death in family, and VT/VF was inducible
at electrophysiological study. From the report by
Maron et al.,24) a single marker of high risk for
sudden death may be suﬃcient to justify consider-
ation for prophylactic deﬁbrillator implantation in
selected patients with HCM, because an important
proportion of ICD discharges occurred in primary
prevention patients who had undergone implantation
for a single risk factor.
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